Sandbox:Sahar: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable" | ||
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Amyloisosis subtype}} | ! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Amyloisosis subtype}} | ||
! | ! rowspan="2" style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|Protein}} | ||
! colspan="3" style="background: #4479BA; width: 100px;" | Organ involvement (%) | |||
! | |||
|- | |- | ||
! style="background: #4479BA; width: 100px;" | | ! style="background: #4479BA; width: 100px;" | Kidney | ||
! style="background: #4479BA; width: 100px;" | | ! style="background: #4479BA; width: 100px;" | Liver | ||
! style="background: #4479BA; width: 100px;" | | ! style="background: #4479BA; width: 100px;" | Heart | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Primary | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Primary | ||
| | |Monoclonal immunoglobulin light chains | ||
| | |50-100 | ||
| | |10-25 | ||
| | |50-100 | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Secondary | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Secondary | ||
| | |Serum amyloid A | ||
| | |50-100 | ||
| | |<10 | ||
| | |_ | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |DRA (dialysis related amyloidosis) | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |DRA (dialysis related amyloidosis) | ||
| | |Beta‐2 microglobulin | ||
| | |_ | ||
| | |_ | ||
| | |_ | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Senile systemic (cardiac) amyloidosis | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Senile systemic (cardiac) amyloidosis | ||
|Transthyretin (wild type) | |||
|_ | |_ | ||
| | |_ | ||
|50-100 | |||
| | |||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meretoja syndrome | | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Meretoja syndrome | ||
| | |Gelsolin | ||
| | |_ | ||
| | |_ | ||
| | |_ | ||
|} | |} | ||
Revision as of 05:46, 10 November 2019
Amyloisosis subtype | Protein | Organ involvement (%) | ||
---|---|---|---|---|
Kidney | Liver | Heart | ||
Primary | Monoclonal immunoglobulin light chains | 50-100 | 10-25 | 50-100 |
Secondary | Serum amyloid A | 50-100 | <10 | _ |
DRA (dialysis related amyloidosis) | Beta‐2 microglobulin | _ | _ | _ |
Senile systemic (cardiac) amyloidosis | Transthyretin (wild type) | _ | _ | 50-100 |
Meretoja syndrome | Gelsolin | _ | _ | _ |
Infection/Inflammation | |||||||||||||||||||||||
Increased production of IL-1/IL-6/TNF-α | |||||||||||||||||||||||
Upregulation of hepatic serum amyloid A production | |||||||||||||||||||||||
SAA production uptake by macrophages | |||||||||||||||||||||||
C-terminal cleavage of SAA | |||||||||||||||||||||||
β-sheet configuration of SAA | |||||||||||||||||||||||
Fibril deposition in extracellular space | |||||||||||||||||||||||
Binding of glycosaminoglycan, serum amyloid P, and lipid components | |||||||||||||||||||||||
Resistant to proteolysis | |||||||||||||||||||||||
The above algorithm is adopted from International Journal of Nephrology and Renovascular Disease |
---|
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
---|---|---|---|---|---|---|
Nephrotic Syndrome and Renal Failure | Secondary (AA) Amyloidosis |
|
|
|
|
|
Primary (AL) Amyloidosis |
|
|
|
|||
Diabetic Nephropathy |
|
|
|
|||
Minimal Change Disease |
|
| ||||
Focal Segmental Glomerulosclerosis | ||||||
Fabry's Disease |
|
|
|
|
| |
Light Chain Deposition Disease |
|
|
| |||
Membranous Glomerulonephritis |
|
|
|
|
| |
Fibrillary-Immunotactoid Glomerulopathy |
|
|
|
|||
Organ System Involvement | Differential Diagnosis | Causes | Clinical Features | Laboratory Findings | Gold Standard Test | Therapy |
Polyneuropathy | POEMS syndrome (Demyelinating) |
|
|
|||
Metabolic Syndrome (Axonal pathology) |
|
|
|
|||
Vitamin Deficiencies (Axonal Pathology) |
|
|
|
| ||
Guillain-Barre Syndrome (Demyelinating) |
|
|
|
|||
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing) |
|
|
|
|
||
Multifocal Motor Neuropathy |
|
|||||
Organ System Involvement | Differential Diagnosis | Causes | Features | Laboratory Findings | Gold Standard Test | Therapy |
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) | Malaria |
|
|
| ||
Kala-azar |
|
|
|
|||
Infective Hepatitis |
|
|
||||
Chronic Myelogenous Leukemia (CML) |
|
|
||||
Lymphoma |
|
|
||||
Primary (AL) Amyloidosis |
|
|
|
| ||
Gaucher's Disease |
|
|
|
|
Example #1
The patient presented with S.O.B. one year after hysterectomy for a leiomyomatous uterus.